TD Cowen initiated coverage on shares of Sionna Therapeutics (NASDAQ:SION – Free Report) in a research note released on Tuesday, Marketbeat reports. The brokerage issued a buy rating on the stock.
Several other research firms have also recently issued reports on SION. Guggenheim began coverage on Sionna Therapeutics in a report on Tuesday. They issued a “buy” rating and a $45.00 price objective on the stock. Stifel Nicolaus assumed coverage on Sionna Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $32.00 price target on the stock.
View Our Latest Stock Analysis on SION
Sionna Therapeutics Trading Up 2.7 %
About Sionna Therapeutics
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Read More
- Five stocks we like better than Sionna Therapeutics
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- GitLab: Get In While It’s Down—Big Rebound Ahead
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Tesla Stock: Finding a Bottom May Take Time
- Insider Trades May Not Tell You What You Think
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
